Table 3.
Tumour responses based on RECIST v1.1 criteria according to the baseline tumour size for each group
Overall, n (%) | BTS ≤ 86 mm, n (%) |
BTS > 86 mm, n (%) |
p-value | |
---|---|---|---|---|
Pembrolizumab group | N = 96 | N = 50 | N = 46 | |
ORR | 57 (59.4) | 31 (62.0) | 26 (56.5) | 0.74 |
DCR | 72 (75.0) | 41 (82.0) | 31 (67.4) | 0.16 |
Chemotherapy group | N = 92 | N = 47 | N = 45 | |
ORR | 15 (16.3) | 8 (17.0) | 7 (15.6) | 1 |
DCR | 55 (59.8) | 31 (66.0) | 24 (53.3) | 0.31 |